• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Navigating cardiotoxicity risk in cancer therapy: the importance of the HFA-ICOS score.

作者信息

Butel-Simoes Lloyd E, Ngo Doan T M, Sverdlov Aaron L

机构信息

Cardiovascular Department, John Hunter Hospital, Lookout Rd, New Lambton Heights, NSW 2305, Australia.

Newcastle Centre of Excellence in Cardio-Oncology, Hunter Medical Research Institute, Hunter New England Local Health District, University of Newcastle and Calvary Mater Newcastle, New Lambton Heights, Newcastle, NSW 2305, Australia.

出版信息

Eur Heart J. 2025 Jan 16;46(3):285-287. doi: 10.1093/eurheartj/ehae624.

DOI:10.1093/eurheartj/ehae624
PMID:39680373
Abstract
摘要

相似文献

1
Navigating cardiotoxicity risk in cancer therapy: the importance of the HFA-ICOS score.应对癌症治疗中的心脏毒性风险：HFA-ICOS评分的重要性。
Eur Heart J. 2025 Jan 16;46(3):285-287. doi: 10.1093/eurheartj/ehae624.
2
The added value of the HFA/ICOS score in the prediction of chemotherapy-related cardiac dysfunction in breast cancer.HFA/ICOS 评分在预测乳腺癌化疗相关心脏功能障碍中的附加价值。
J Cardiovasc Med (Hagerstown). 2024 Mar 1;25(3):218-224. doi: 10.2459/JCM.0000000000001589. Epub 2024 Feb 2.
3
The new HFA/ICOS risk assessment tool to identify patients with chronic myeloid leukaemia at high risk of cardiotoxicity.新型 HFA/ICOS 风险评估工具，用于识别慢性髓性白血病患者发生心脏毒性的高危风险。
ESC Heart Fail. 2022 Jun;9(3):1914-1919. doi: 10.1002/ehf2.13897. Epub 2022 Mar 31.
4
Anthracycline-induced cardiovascular toxicity: validation of the Heart Failure Association and International Cardio-Oncology Society risk score.蒽环类药物所致心血管毒性：心力衰竭协会和国际心脏肿瘤学会风险评分的验证
Eur Heart J. 2025 Jan 16;46(3):273-284. doi: 10.1093/eurheartj/ehae496.
5
Heart Failure Association-International Cardio-Oncology Society Risk Score Validation in HER2-Positive Breast Cancer.心力衰竭协会-国际心脏肿瘤学会风险评分在HER2阳性乳腺癌中的验证
J Clin Med. 2023 Feb 6;12(4):1278. doi: 10.3390/jcm12041278.
6
Cardiovascular toxicity induced by TKIs in patients with chronic myeloid leukaemia: Are women and men different?酪氨酸激酶抑制剂对慢性髓性白血病患者的心血管毒性：男性和女性有差异吗？
ESC Heart Fail. 2025 Apr;12(2):1447-1454. doi: 10.1002/ehf2.15165. Epub 2025 Jan 9.
7
Cardiovascular events in CML patients treated with Nilotinib: validation of the HFA-ICOS baseline risk score.接受尼洛替尼治疗的慢性粒细胞白血病患者的心血管事件：HFA-ICOS基线风险评分的验证
Cardiooncology. 2024 Jul 15;10(1):42. doi: 10.1186/s40959-024-00245-x.
8
Incidence of cardiotoxicity and validation of the Heart Failure Association-International Cardio-Oncology Society risk stratification tool in patients treated with trastuzumab for HER2-positive early breast cancer.曲妥珠单抗治疗 HER2 阳性早期乳腺癌患者的心脏毒性发生率和心力衰竭协会-国际心脏肿瘤学会风险分层工具的验证。
Breast Cancer Res Treat. 2021 Jul;188(1):149-163. doi: 10.1007/s10549-021-06192-w. Epub 2021 Apr 5.
9
Baseline cardio-oncologic risk assessment in breast cancer women and occurrence of cardiovascular events: The HFA/ICOS risk tool in real-world practice.乳腺癌女性的基线心脏肿瘤学风险评估与心血管事件的发生：现实世界实践中的HFA/ICOS风险工具
Int J Cardiol. 2022 Feb 15;349:134-137. doi: 10.1016/j.ijcard.2021.11.059. Epub 2021 Nov 27.
10
Cardiotoxicity of BRAF/MEK Inhibitors According to HFA/ICOS Cardiotoxicity Risk Category.根据HFA/ICOS心脏毒性风险类别，BRAF/MEK抑制剂的心脏毒性
JACC CardioOncol. 2023 Dec 19;5(6):848-849. doi: 10.1016/j.jaccao.2023.09.006. eCollection 2023 Dec.

引用本文的文献

1
Lifestyle and Pharmacological Interventions to Prevent Anthracycline-Related Cardiotoxicity in Cancer Patients.预防癌症患者蒽环类药物相关心脏毒性的生活方式和药物干预措施。
J Cardiovasc Dev Dis. 2025 Jun 4;12(6):212. doi: 10.3390/jcdd12060212.